The evaluation of KRAS mutation status in CRC patients has a crucial prognostic role, since patients carrying KRAS mutations have a poor response to anti-EGFR therapy [14, 15] and show an increased cumulative incidence of metastatic disease [16]. This evidence concerns the gene KRAS and metastatic neoplasm.